TippingPoint Biosciences

TippingPoint Biosciences is dedicated to creating new approaches to treat diseases of genome packaging such as hard-to-treat cancers and improve the quality of life of the patients. Launched in 2023, TippingPoint Biosciences is an SF-based therapeutic company with a mission to improve and save the lives of patients who suffer from diseases with high unmet needs. Co-founded by Dr. Laura Hsieh, American Cancer Society Fellow and Dr. Geeta J. Narlikar, UCSF Professor of Biochemistry and Biophysics and National Academy of Sciences Member, TippingPoint Biosciences is a startup that was inspired by the ground-breaking discoveries made in Dr. Narlikar’s laboratory at UCSF. The company has built a new type of drug discovery platform to identify treatments for diseases caused by defects in DNA packaging, which include several hard-to-treat cancers. TippingPoint’s proprietary platform addresses major limitations and challenges seen in the healthcare space by recreating the biological context of cancer-driving chromatin states in a controlled, cell-free environment. Rather than targeting a single factor, TippingPoint’s platform focuses on disrupting or restoring the unique protein-protein and protein-DNA networks that package cell genomes. Unlike individual factors that may have similar functions in both healthy and diseased cells, the DNA packaging networks in cancer cells are significantly different, and can be exploited to enhance drug specificity and limit drug resistance. As the only company that is directly targeting genome packaging states known to cause disease, TippingPoint is developing an entirely new class of drugs to treat disease. To learn more, please visit https://tippingpointbiosciences.com/.